Open AccessTreatment patterns and outcomes among nontransplant newly diagnosed multiple myeloma patients in Spain
Author(s) -
JoséÁngel HernándezRivas,
Mario Arnao,
José María Arguiñano Pérez,
Araceli OrtízRubio,
Esther González García,
Dunia de Miguel,
Dasha Cherepanov,
Dorothy Romanus,
Katharina Verleger,
Courtney Johnson,
Shelby Corman,
Marta Grande,
Ernesto Pérez Persona
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-0301
Subject(s) - medicine , proteasome inhibitor , multiple myeloma , retrospective cohort study , oncology
Aim: To describe treatment patterns and outcomes in nontransplant newly diagnosed multiple myeloma (NDMM) patients in Spain. Methods: This retrospective study included two cohorts of NDMM patients diagnosed between 1 January 2012 to 31 December 2013 and 1 April 2016 to 31 March 2017. Results: Among 113 patients, proteasome inhibitor (PI) + alkylator combinations (49%) and PI-based regimens without an alkylator (30%) were the most common first-line (1L) therapies. Use of PI + immunomodulatory drug-based regimens increased between the cohorts; PI-based regimens without an alkylator/immunomodulatory drug decreased. Use of 1L oral regimens was low but increased over time; use of maintenance therapy was low across both periods. Median 1L duration of treatment was 6.9 months. Conclusion: Short 1L duration of treatment and low use of 1L oral regimens and maintenance therapy highlight unmet needs in NDMM.